MP Biomedicals completes its range of in vitro diagnostic tests for infectious diseases with new immunochromatographic-based qualitative rapid tests.The new diagnostic kits by MP Biomedicals leverage cutting-edge technology to deliver precise results, enabling healthcare professionals a rapid and accurate detection of Helicobacter pylori, Salmonella typhi and Vibrio cholerae serogroups O1 and O139.
FDA Expands Enhertu Approval to HER2-Ultralow Breast Cancer
The FDA expanded the approval of trastuzumab deruxtecan (T-DXd, Enhertu) to include treatment of unresectable/metastatic hormone receptor (HR)-positive, HER2-low/ultralow breast cancer. Approval stipulates use in